Key result
SGLT2 inhibitors exert cardioprotective effects in heart failure by modulating endothelial ion channels, specifically by lowering intracellular calcium through the inhibition of NHE1 and NCX.
Why the study?
Heart failure is closely related to endothelial dysfunction involving ion channels regulating intracellular calcium, and the mechanisms of SGLT2 inhibitors on these channels remain to be clarified.
Answers are grounded in this paper and cite their sources.
This review provides a mechanistic framework explaining how SGLT2 inhibitors improve cardiovascular outcomes in heart failure by targeting endothelial dysfunction and restoring endothelial ion channel homeostasis.
Heart failure (HF) is a life-threatening cardiovascular disease associated with high mortality, diminished quality of life, and a significant economic burden on both patients and society. The pathogenesis of HF is closely related to the endothelium, where endothelial ion channels play an important role in regulating intracellular Ca2+ signals. These ion channels are essential to maintain vascular function, including endothelium-dependent vascular tone, inflammation response, and oxidative stress. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown promising cardiovascular benefits in HF patients, reducing mortality risk and hospitalization in several large clinical trials. Clinical and preclinical studies indicate that the cardioprotective effects of SGLT2i in HF are mediated by endothelial nitric oxide (NO) pathways, as well as by reducing inflammation and reactive oxygen species in cardiac endothelial cells. Additionally, SGLT2i may confer endothelial protection by lowering intracellular Ca2+ level through the inhibition of sodium-hydrogen exchanger 1 (NHE1) and sodium-calcium exchanger (NCX) in endothelial cells. In this review, we discuss present knowledge regarding the expression and role of Ca2+-related ion channels in endothelial cells in HF, focusing on the effects of SGLT2i on endothelial NHE1, NCX as well as on vascular tone.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors exert cardioprotective effects in heart failure by modulating endothelial ion channels, specifically by lowering intracellular calcium through the inhibition of NHE1 and NCX.
Synapse has enriched 10 related papers. Consider them for comparative context: